Literature DB >> 32008808

E-cigarette use related lung disease, review of clinical and imaging findings in 3 cases.

Kianoush Ansari-Gilani1, Andrew M Petraszko2, Catalina V Teba3, Allen R Reeves4, Amit Gupta5, Aekta Gupta6, Nikhil H Ramaiya7, Robert C Gilkeson8.   

Abstract

Electronic-cigarette use (vaping), has gained popularity among the young adult population, causing an alarming rise in electronic-cigarette, or vaping, product use-associated lung injury (EVALI). The specific chemical agent(s) responsible for lung injuries remains to be further investigated, but tetrahydrocannabinol, the active ingredient in marijuana, and vitamin E acetate are involved in most cases. A variety of pulmonary diseases causing different imaging findings have been described with EVALI. The clinical and imaging findings of three cases recently seen in our emergency department are reviewed.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomography; E-cigarette; Imaging; Lung injury; Vaping

Mesh:

Substances:

Year:  2020        PMID: 32008808     DOI: 10.1016/j.hrtlng.2020.01.005

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  3 in total

1.  COVID-19 pneumonia versus EVALI, distinguishing the overlapping CT features in the COVID-19 era.

Authors:  Kianoush Ansari-Gilani; Andrew M Petraszko; Robert C Gilkeson
Journal:  Heart Lung       Date:  2020-06-23       Impact factor: 2.210

Review 2.  A Systematic Literature Review of E-Cigarette-Related Illness and Injury: Not Just for the Respirologist.

Authors:  Anna Tzortzi; Melpo Kapetanstrataki; Vaso Evangelopoulou; Panagiotis Beghrakis
Journal:  Int J Environ Res Public Health       Date:  2020-03-27       Impact factor: 3.390

Review 3.  Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.

Authors:  Shawn J Rice; Victoria Hyland; Madhusmita Behera; Suresh S Ramalingam; Paul Bunn; Chandra P Belani
Journal:  J Thorac Oncol       Date:  2020-08-29       Impact factor: 15.609

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.